Th e Implex TI CA LZ 300 I is a tot all y impl antable eleetroni e hearing de viee for the surg iea l treatm ent of se leeted pati ents who have mo derate to seve re hi gh -frequen cy se nso rine ur al hearing loss (S N HL).' TI C A has obta ined CE ap pro va l for ro utine use in Euro pe. Th e author has been implantin g TI CA sinee 1998.1.2 T he read er is referred to a reeent re vie w of im planta ble hearin g aids pub lished by Hu tte nbrink.'
Introduction
Th e Implex TI CA LZ 300 I is a tot all y impl antable eleetroni e hearing de viee for the surg iea l treatm ent of se leeted pati ents who have mo derate to seve re hi gh -frequen cy se nso rine ur al hearing loss (S N HL).' TI C A has obta ined CE ap pro va l for ro utine use in Euro pe. Th e author has been implantin g TI CA sinee 1998.1.2 T he read er is referred to a reeent re vie w of im planta ble hearin g aids pub lished by Hu tte nbrink.'
Materials and methods
T he nCA LZ 300 I is ma nufaetured by Imple x AG Hearing Teehnology in M un ieh (w ww .implex. de; Imple x has a U.S . offiee in Raleigh , N.C. ). The de viee eo ns ists of three main parts : the aetu ator , th e me mbran e sensor (miero pho ne), and the processor module (fig ure I) . The e ntire sys te m is designed to be impl ant ed int o th e mastoid eavi ty and tyrnpanu m.'
The actuator. Th e ae tuato r, whie h we ighs OA g, is mad e of titan ium (me dical gra de 2, AST M F67 ) and was design ed to be impl ant ed into th e mastoid ea vity and tyrnp anum .' Transfer of meeh ani eal ose illa tions to an os siele in th e m iddl e eal' is e ffeeted by a titan ium eo upling rod OI' cli p. The tra nsdu eer is highl y tu ned , w ith a resonan ee freq ue ney in the ra nge of 7 to 10kHz, dep en din g o n the dynam ie ma ss load . Bel ow th is resona nee and do wn to the low freq ue neies, the freq ue ney resp o nse is fla t, wi th a sma ll ripple ofl ess than ±I dB . Vi bratio n amplitude at the lo w an d middle frequ en eies is abo ut 60 nm, with a tran sd ueer voltage of I V, eo rre spo nding to an eq uiva le nt so und pressure le vel (SPL) of 100 dB SPL up to I kHz. A t the hig her fre q ue neies, up to 10 kH z, the o utput le vel inc reases to beyond 130 dB SPL. No nl inear distor tio ns at Fromthe Departm ent of Otolaryngo logy, the Unive rs ity ofTübinge n, Ger many. Repr int req uests: Hans Peter Ze nner, MO , Departm ent of OtoJaryngo logy, Universi ty of T übinge n, Silch erst rasse 5, 72076 T uebin gen , Germany . Phone: +49-707 1-298-4 164 ; fax: +49-707 1-295-674; e-mai l: ze nner@ uni-llIebinge n.de 770 maxirnu m volume ( I V) are small (T HD <0 . 1%) throughout the entire tr an sfer range.
Beeause of its short o n-ti me (50 us) and short off-t irne (-2 ms), the dyn ami e proper ties of the tra nsd ueer allow for good tran sm issio n of audio signa ls and fas t eha nge s in the time domain-that is, of plosives in speee h sig nals . Th e elee trie power eo nsumption at full vo lume a nd broadband signals is in the regi on of I u W . The herm eti eall y sealed se nso r is implant ed in the poster io r wall of the auditcry ean al.
The sensor. The membrane se nsor, whi eh also weighs OA g, has a membrane di ameter of 4.5 m m. Despi te this miniaturi zation, the so und pressure tra nsfer fune tion is fla t and the bandw idth a mo unts to appro xi ma tely 10 kH z. Beeause of its hi gh tu ning and high no -Ioad resonan ee freq ue ney , the m ie rophon e is rat her insens itive to po stsurg ieal eh ang es to the load ing mass on th e m ieroph on e membran e produeed by the eoveri ng ski n of the audito ry ea nal. Tran sfer fae to r at 1,000 Hz is approximately 1.5 mV/Pa.
Beeause of its sma ll mass, the se nso r is hi ghly in sen sitive to e nvironme nta l meeh ani eal distu rb an ees. It is mad e of titan iu m and is he rm eti eall y se aled . Full met al e nea psulatio n a nd add itio nal int ern ai e leetro nie eo mpo ne nts proteet the sens or against e nviro nme nta l elee tro magnetie in flue nees. A mod ul e suited for sube uta neo us im plantation be hind the eal' eontains the sig na l-pro eess ing eleetroni es and an integ ra ted battery th at can be reeharg ed tra nseut aneou sly w ith a portab le charger.' The eleetronies' basie audiolog ie fea tures are pro vid ed by a flexibl e, digitally progr a mm abl e, thr ee-cha nnel AGC sys te m wit h a peak cli pp ing fun et io n. T ot al band w idth is app roximat ely 10 kH z.
Batt er y reeharging time is abo ut 2 ho urs an d the im plant ope rating tim e is 50 hou rs. How e ver , most patie nts report that the y reeharge th e ba tter y fo r 30 to 45 mi nute s on a dai ly ba sis. W he n th e batt ery' s lifet im e e xpires , detachab le se nso r and transdu eer eo nnee to rs allow for the replaee me nt of th e proc esso r modul e while the se nso r and ac tua to r are left in situ. A small wireles s re mo te-eo ntro l New Techniques in EN[: Spedalty Instruments for APC I~1 and Electrosurgery APC (Argon Plasma Coagulation) permits safe hernostasis and effective devitalization of pathologic tissues. Specially developed instruments now make the advantages of APC, along with ERBE electrosurgical technology, available for ENT:
• Limited penetration depth with reduced risk of perforation • on-contact technology • 0 vaporization, no carbonization • Easy to use • Improved postoperative wound healing
The nasal turbinates are effectively reduced long-term in hyperplasia ( Fig.l) .
APC permits non-contact, homogeneous and highly effective treatment of superficial lesions of the oral mucosa such as granuloma and leucoplakia ( Fig. 2 ).
APC's limited penetration depth offers maximum protection against perforation in treatments of papillomatosis ( Fig. 3 ).
Telangiectatic lesions in the nasal mucosa can be treated as weil as lesions in the skin and mucosa of the lips and oral cavity ( Fig. 4 ). device allows the patient to turn the device on and off, adjust the volume, and select from among four different hearing programs.
Selectedinstruments for ENT
Theprocessor module. The processor module incorporates an energy source and a digitally programmable three-channel audioprocessor? Similar to a CI receiver, the processor module is implanted subcutaneously behind the auricle.
The three TICA parts are not permanently coupled. Both the sensor and actuator contain wires with plugs that are connected to the processor unit by the surgeon. In case of a loss of energy, the processor module can be easily exchanged while the actuator and sensor both remain implanted.
Results and discussion
The heart of the implant is a disk-shaped heteromorph piezoelectric actuator that is coupled to the Unlike the loudspeaker of a conventional hearing aid, the actuator does not produce sound but micromechanical vibrations. These allow the ossicular chain to be driven in the physiologic amplitude range. The actuator heteromorph consists of two different disks: a piezoelectric disk and a titanium disk. The piezoelectric disk drives the titanium disk, resulting in the desired vibrations. These are attached to the incus with a couding axis that has a A coupling element at its tip (figure 2). Titanium clips are available for the long incus process. For the incus body, the titanium tip of the coupling rod is inserted into a laser-made bony indentation and fixed with ionomeric cement ge1. 6 In vitro studies with laser Doppler velocimetry revealed a broadband and flat frequency response from 50 Hz to 10 kHz, producing power equivalent to 100 dB at 1 kHz and up to I30 dB at 7 kHz (figure 3). Thus, the TICA LZ3001 is specifically Animal experiments revealed auditory brainstem responses that were identical to those for sound stimulation.8 Energy consumption was so low that a totally implantable device could be conceived. A totally implantable device requires an implantable sound sensor (microphone). Because of the outer ear's unique acoustic properties that contribute to noise suppression and auditory orientation, a sensor's best location is thought to be the eardrum, ossicles, or outer ear canal. Thus, amembranous sensor was developed to be implanted subcutaneously in the dorsal wall of the external auditory canal.g In its interior, it possesses a microphone that is stimulated by the sensor's subcutaneous titanium membrane. Similar to the actuator, the sensor's frequency response could be A prospective intra-individually co ntroll ed study with an enrollme nt o f 20 con secutive pati ent s who had an irreversible, chronic, bilateral , moderate to sev ere SNHL allo wed for a 6-month follow up o f 19 per-protoc ol patient s. All patients had failed to benefit fro m co nventiona l hearing aid s. Schuller ' s x-ray revealed the correct po stopera tive anatomic locati on of the implants (figure 6). 10 Discrimination of phoneti cally bal anced mon osyll ables was improv ed significantly in 18 of the 19 patients and reach ed 100% in 14 patients (preo perative : 4 patient s). One hundred pereent of the standardize d se ntences were und erstood by 15 of the pati ent s. In the pres en ce of noise, the se ntenc e recognition threshold (sco re of 50 %) was from -2 to I dB , and flatulenee 4%. The incidenee of Gl adve rse reaet ions, ineludi ng diarrhea and loose stools, in pedi atri e patients reeeiving the suspension was eomparable to that see n in adult palients reeeiving tablets. Symptoms usually responded to symptomatie therapy or eeased when SUPRAX was diseontinued. Several patients developed seve re diarrhea and/or doeumented pseudomem branous eolitis, and a few required hospitali zation.
The following adverse reaetions have been reported following the use of SUPRAX. Incidenee rates we re less than 1 in 50 (Iess than 2%), exeept as noted above for Gl eve nts. G/ (see above) : Di arrhea, loose steots. abdominal pai n, dyspepsia, nausea, and vomiting. Severa l cases 01 doeumented pse udome mbranous eolitis were identil ied duringthe studies; onset of symptoms may oeeur during or after therapy. Hypersensi-/ivityReaetions: Skin rashes, urtiearia, drug lever, and pruritus. Erythema multiforme, Steve ns-Jo hnson syndrome , and serum siekness-Iike reaetions have been reported. Hepatie: Transient elevations in SG PT, SG OT, and alkaline phosphatase. Renal: Tr ansient elevations in BUN or ereatinine. CentralNervous System: Headaches or dizziness. Hemie and Lymphatie Systems: Transient throm boeytopenia, leukopeni a, and eos inophilia. Prolongation in prothrombin time was see n rarel y. Dther. Ge nital pruritus, vaginitis, eandidiasis.
In addition to the adverse reaetions Iisted above whieh have bee n observed in pati ents treated with SUPRAX, the following adverse reaetions and altered laboratory tests have beenreported lor eephalosporin-elass antibioties: AdverseReaetions: Allergie reaetions ineluding anaphylaxis, toxie epidermal neerol ysis, supe rinleetion, renal dysfunetion,toxie nephropathy, hepatie dyslunetioninel uding cholestasis. aplastie anemia, hemol ylieanemia, hem orrhage, and eo litis. Administer antibioties, ineludingSUPRAX, eautiously to anypanent who has demonstrated some lorm of allergy, partieul arl y to drugs. Treatmentwith broad -speetrumantibioties, ineluding SUPRAX, al ters the normal flora 01 the eolon and may permi t overgrowth 01 elostridia. Stud ies indieate that a toxin prod ueed by Ciostridium diffieHe is a primary eause of severeantibiotie-assoeiated diarrhea ineludi ng pseudomemb ran ous eolitis.
Pseu domembranous eolitis has been reported with the use 01 SUPRAX and other broadspeetrum antibioties (ineluding maeroli des, semisynthetie penieillins, andeephalosporins); therefore, it is important to eonsiderthis diag nosis in patients who develo p diarr hea in association with the use 01 antibioties. Symptoms of pseudom embranous eolitis may oeeur during or after antibiotie treatmentand may range in severity Irom mild to lifethreaten ing. Mild cases of pse udomembranous eolitis usually respond to drug diseontinuation alone. In moderate to severe cases, management shou ld ineludefluids, electrolytes, and protein supplementation. It the eolitis does not improve after the drug has been diseontinued , or if the sym ptoms are severe, oral vaneomyein is the drug of choice for antibiotie-assoeiated pseudomem branous eolitis prod ueed by C. diffieHe. Other eauses 01eolitis shoul d be exeluded. was co n-eet by 89.5%. Analog sca ling revea led a natural sound impression of 100% (median: +17.5%,-0%; preoperative: 70%) and only 5% distortion (preo perative : 30%). Using the standa rd ized Gothenburg profile subjective eva luatio n of hear ing, patients' orientation, social beh av ior, and self-confiden ee were increased to 80 to 88% of the ma ximum score; there were 17 responders and three nonresponders. Only mild adverse eve nts were observed, most of whic h resolved. Thu s, the treatm ent of SNHL with the tota lly impl antabl e hearing system appea rs to be an efficie nt and safe meth od for treatin g patient s who ca nnot benefit fro m hearing aids.
